Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) just unveiled an announcement.
On March 4, 2026, Microbot Medical announced its alignment with the American Medical Association’s late-2025 policy to strengthen protections for healthcare professionals and trainees from occupational ionizing radiation. The company highlighted that the AMA’s focus on research, personal protective equipment and education underscores growing demand for technologies that can reduce exposure in interventional procedures.
Microbot emphasized that its LIBERTY Endovascular Robotic System, which is remotely operated and allows clinicians to work away from the radiation source, achieved a 92% relative reduction in radiation exposure in the ACCESS-PVI study. The system is marketed as a way to mitigate long-term health risks from radiation, lessen the physical burden of heavy protective gear and help address staffing shortages, particularly in interventional radiology.
The company also noted that radiation risks and musculoskeletal strain disproportionately deter women from entering or advancing in endovascular specialties, positioning LIBERTY’s wireless and seated-operation capabilities as tools to improve working conditions and inclusivity. Having begun a Limited Market Release of LIBERTY in late 2025, Microbot plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to accelerate adoption among hospitals and healthcare providers.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures, aimed at improving precision, efficiency and safety in vascular care.
Backed by a substantial intellectual property portfolio, Microbot targets hospitals and healthcare providers seeking to enhance operator safety and workflow in interventional radiology and related specialties. The company is positioning LIBERTY as a tool to address radiation exposure, physical strain and staffing challenges that affect physicians and other clinicians in these high-demand fields.
Average Trading Volume: 1,981,248
Technical Sentiment Signal: Hold
Current Market Cap: $160.5M
Learn more about MBOT stock on TipRanks’ Stock Analysis page.